Alcon Inc. ALC reported mixed second-quarter results, after the closing bell on Tuesday.Alcon reported quarterly earnings of 74 cents per share which beat the analyst consensus estimate of 73 cents per share. The company reported quarterly sales of $2.48 billion which missed the analyst consensus estimate of $2.52 billion.“We are pleased with our solid second-quarter results, which were driven by robust demand for our innovative products, our balanced geographic footprint and strong execution by our team. T ...

Alcon Inc. (NYSE:ALC) Q2 2024 Earnings Conference Call August 21, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Jeff Johnson - Baird Graham Doyle - UBS Veronika Dubajova - Citi Ryan Zimmerman - BTIG David Adlington - JPMorgan Patrick Wood - Morgan Stanley Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Company Anthony Petrone - Mizuho Group ...

Alcon, Inc. (ALC) delivered core earnings per share (EPS) of 74 cents in the second quarter of 2024, up 7.2% from the year-ago quarter’s figure (up 15% at the constant exchange rate or CER). The figure came in line with the Zacks Consensus Estimate.Alcon reports ‘core’ results based on non-IFRS (International Financial Reporting Standards) measures. In the second quarter, the company’s diluted EPS was 45 cents, up 32.4% year over year.Revenues in DetailAlcon’s net sales to third parties in the second quarte ...

For the quarter ended June 2024, Alcon (ALC) reported revenue of $2.48 billion, up 3.3% over the same period last year. EPS came in at $0.74, compared to $0.69 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $2.52 billion, representing a surprise of -1.43%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.74.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to W ...

Alcon (ALC) has been gaining from a strong pipeline and its focus on research and innovation. Market share gains also aid growth. The stock currently carries a Zacks Rank #2 (Buy).In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon currently leads the market with more than 60% share globally and over 80% share in the United States. In Surgical, the company maintains a strong market share in PCIOLs, driven by strong demand for products like PanOptix and Vivity despite new market entrants. Vivity's non- ...

In its upcoming report, Alcon (ALC) is predicted by Wall Street analysts to post quarterly earnings of $0.74 per share, reflecting an increase of 7.3% compared to the same period last year. Revenues are forecasted to be $2.52 billion, representing a year-over-year increase of 4.8%. Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company reveals ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What a ...

Alcon (ALC) has been gaining from a strong market rebound. The company’s pipeline strength and focus on research and innovation are also impressive. The stock carries a Zacks Rank #2 (Buy) currently.Alcon leads the market in Presbyopia-correcting Intraocular Lens (PCIOLs), with over 60% of the global share and more than 80% share in the United States. In Surgical, the company has maintained a strong share in PCIOLs, solidifying its market-leading position driven by strong demand for products like PanOptix a ...

The Medical Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. The industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on and so forth.The medical instruments space has been benefiting from the ongoing merger and acquisition trend. The smaller and mi ...

Alcon Inc. (ALC) recently received the FDA’s 510(k) clearance for its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS). Both the systems will be introduced from Alcon’s Unity portfolio.Unity VCS and Unity CS are designed to deliver transformative surgical innovation. With these proprietary technologies, the eye care major expects to hold its market-leading position in the global cataract and retina procedural packs (consumables used in each surgery) market.About Unity VCS and Unity C ...